GGrantIndex
← Leaderboards

Christopher Hooper Goss

Seattle Children'S Hospital

$12,695,799
Attributed
$16,123,371
Total exposure
18
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.2M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,514,820 · 18
FDA$4,308,209 · 2

By mechanism

UM1$9,412,172 · 2
R01$8,083,617 · 3
P30$7,232,371 · 7
K23$626,265 · 1
R21$425,100 · 1
M01$43,504 · 6

Top collaborators

Most similar at Seattle Children'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Cystic Fibrosis

Research focus

Cystic FibrosisAdultCystic Fibrosis PatientsResearch PersonnelChronicProgramsLinkResourcesClinical TrialsClinical ResearchNovel TherapeuticsPharmaceutical PreparationsOutcome MeasureBaseLungSymptomsCystic Fibrosis Transmembrane Conductance RegulatorCollaborationsRespiratory PhysiologyFundingTranslational ResearchInfectionDrug DevelopmentGrowth

Grant awards (52)

Center for Cystic Fibrosis Translational Research in the Post-CFTR modulator Era$1,313,622
P30 · FY2025 · DK · contact PI
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$739,415
R01 · FY2025 · FD · contact PI
Clinical and Specimen Core$248,055
P30 · FY2025 · DK · contact PI
Administrative Core$210,875
P30 · FY2025 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,209,483
P30 · FY2024 · DK · contact PI
Clinical Core$235,676
P30 · FY2024 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,211,277
P30 · FY2023 · DK · contact PI
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$716,405
R01 · FY2023 · FD · contact PI
Clinical Core$235,676
P30 · FY2023 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,213,036
P30 · FY2022 · DK · contact PI
Clinical Core$235,676
P30 · FY2022 · DK · contact PI
Clinical Core$235,676
P30 · FY2021 · DK · contact PI
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$853,982
R01 · FY2020 · FD · contact PI
Clinical Core$235,676
P30 · FY2020 · DK · contact PI
Clinical Core$210,110
P30 · FY2019 · DK · contact PI
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis$399,994
R01 · FY2018 · FD · contact PI
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis$399,209
R01 · FY2017 · FD · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$92,308
UM1 · FY2017 · HL · contact PI
Ancillary Study 1$1,805,147
UM1 · FY2016 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,805,147
UM1 · FY2016 · HL · contact PI
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis$399,680
R01 · FY2016 · FD · contact PI
Clinical Core$217,358
P30 · FY2016 · DK · contact PI
Ancillary Study 1$1,853,439
UM1 · FY2015 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,853,439
UM1 · FY2015 · HL · contact PI
Clinical Core$220,175
P30 · FY2015 · DK · contact PI
Early Intervention in Pulmonary Exacerbation in CF$717,087
R01 · FY2014 · HL · contact PI
Ancillary Study 1$1,001,346
UM1 · FY2013 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,001,346
UM1 · FY2013 · HL · contact PI
Early Intervention in Pulmonary Exacerbation in CF$706,945
R01 · FY2013 · HL · contact PI
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic Fibrosis$399,524
R01 · FY2013 · FD · contact PI
Early Intervention in Pulmonary Exacerbation in CF$761,712
R01 · FY2012 · HL · contact PI
Early Intervention in Pulmonary Exacerbation in CF$779,929
R01 · FY2011 · HL · contact PI
Early Intervention in Pulmonary Exacerbation in CF$809,735
R01 · FY2010 · HL · contact PI
A pharmacokinetic and safety study of IV gallium nitrate (Ganite) in cystic fibro$200,000
R01 · FY2010 · FD · contact PI
A pharmacokinetic and safety study of IV gallium nitrate (Ganite) in cystic fibro$200,000
R01 · FY2009 · FD · contact PI
Environmental Effects on Lung Function in Cystic Fibrosis Patients$191,100
R21 · FY2008 · ES · contact PI
Environmental Effects on Lung Function in Cystic Fibrosis Patients$234,000
R21 · FY2007 · ES · contact PI
Quality of Life in patients with severe Cystic Fibrosis$125,253
K23 · FY2007 · HL · contact PI
CF RESPIRATORY SYMPTOM QUESTIONNAIRE$763
M01 · FY2007 · RR · contact PI
QUALITY OF LIFE IN ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$152
M01 · FY2007 · RR · contact PI
QUALITY OF LIFE IN ADULTS AND ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$75
M01 · FY2007 · RR · contact PI
Quality of Life in patients with severe Cystic Fibrosis$125,253
K23 · FY2006 · HL · contact PI
STUDY OF ORALLY ADMINISTERED CURCUMINOIDS IN ADULT SUBJECTS WITH CYSTIC FIBROSIS$20,674
M01 · FY2006 · RR · contact PI
QUALITY OF LIFE IN ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$7,443
M01 · FY2006 · RR · contact PI
QUALITY OF LIFE IN ADULTS AND ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$1,655
M01 · FY2006 · RR · contact PI
Quality of Life in patients with severe Cystic Fibrosis$125,253
K23 · FY2005 · HL
QUALITY OF LIFE IN ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$5,706
M01 · FY2005 · RR
QUALITY OF LIFE IN ADULTS AND ADOLESCENTS WITH SEVERE CYSTIC FIBROSIS$3,566
M01 · FY2005 · RR
Quality of Life in patients with severe Cystic Fibrosis$125,253
K23 · FY2004 · HL
Quality of Life in adolescents with severe cystic fibrosis$2,169
M01 · FY2004 · RR
Quality of life in adults and adolescents with severe Cystic Fibrosis$1,301
M01 · FY2004 · RR
Quality of Life in patients with severe Cystic Fibrosis$125,253
K23 · FY2003 · HL